Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Assets: 2019-2024

Historic Current Assets for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $720.7 million.

  • BridgeBio Pharma's Current Assets rose 88.80% to $839.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $839.4 million, marking a year-over-year increase of 88.80%. This contributed to the annual value of $720.7 million for FY2024, which is 50.90% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Current Assets is $720.7 million, which was up 50.90% from $477.6 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Current Assets ranged from a high of $888.9 million in FY2021 and a low of $477.6 million during FY2023.
  • Moreover, its 3-year median value for Current Assets was $548.9 million (2022), whereas its average is $582.4 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Current Assets slumped by 38.25% in 2022, and later spiked by 50.90% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Current Assets (Yearly) stood at $642.8 million in 2020, then soared by 38.27% to $888.9 million in 2021, then slumped by 38.25% to $548.9 million in 2022, then dropped by 12.98% to $477.6 million in 2023, then skyrocketed by 50.90% to $720.7 million in 2024.